Cancer patients have misconceptions about immunotherapy, expecting it to be a huge breakthrough in efficacy but with little or no knowledge about the toxicities, Australian research shows. According to a series of in-depth interviews with 29 Australian patients receiving pembrolizumab for their stage IV melanoma, hope is the key issue underpinning treatment decisions. Patients have ...
Already a member?
Enter your email to keep reading.